+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

VEGF polymorphisms and survival in early-stage non-small-cell lung cancer



VEGF polymorphisms and survival in early-stage non-small-cell lung cancer



Journal of Clinical Oncology 26(6): 856-862



Polymorphisms in the VEGF gene have been identified that are believed to have functional activity. We hypothesized that such polymorphisms may affect survival outcomes among early-stage non-small-cell lung cancer (NSCLC) patients. We evaluated the relationship between VEGF polymorphisms and overall survival (OS) among patients with early-stage NSCLC treated with surgical resection at Massachusetts General Hospital from 1992 to 2001. We specifically investigated the VEGF polymorphisms +936C>T (rs3025039), -460T>C (rs833061), and +405G>C (rs2010963). Analyses of genotype associations with survival outcomes were performed using Cox proportional hazards models, Kaplan-Meier methods, and the log-rank test. There were 462 patients and 237 deaths. Patients carrying the variant C allele of the VEGF +405G>C polymorphism had significantly improved survival (crude hazard ratio [HR] = 0.70; 95% CI, 0.54 to 0.90; P = .006; adjusted HR = 0.70; 95% CI, 0.54 to 0.91; P = .008). Five-year OS for patients carrying the variant C allele of the VEGF +405G>C polymorphism was 61% (95% CI, 54% to 67%) versus 51% (95% CI, 43% to 59%) for those who had the wild-type variant. There was a trend toward improved survival among patients carrying the variant T allele of the VEGF +936C>T polymorphism (crude HR = 0.74; 95% CI, 0.53 to 1.03; P = .07; adjusted HR = 0.73; 95% CI, 0.52 to 1.03; P = .07). Moreover, patients with higher number of variant alleles of the +405G>C and +936C>T polymorphisms had better survival. There was no association found with the -460T>C polymorphism. Polymorphisms in VEGF may affect survival in early-stage lung cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056827025

Download citation: RISBibTeXText

PMID: 18281657

DOI: 10.1200/jco.2007.13.5947


Related references

AKT1 polymorphisms and survival of early stage non-small cell lung cancer. Journal of Surgical Oncology 105(2): 167-174, 2012

Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer. Clinical Cancer Research 15(5): 1794-1800, 2009

Polymorphisms in ERCC2 and overall survival (OS) in early stage non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 23(16_Suppl): 9524-9524, 2016

Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients. Cancer Epidemiology Biomarkers and Prevention 15(11): 2239-2245, 2006

Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. Journal of Clinical Oncology 27(34): 5823-5829, 2009

Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer. Annals of Surgical Oncology 17(10): 2608-2618, 2010

Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non-small-cell lung cancer. Cancer Science 101(11): 2436-2442, 2010

Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis 31(6): 1080-1086, 2010

A case of long-term survival with stage IV small cell lung cancer and early-stage central-type squamous cell lung cancer treated by photodynamic therapy. Japanese Journal of Clinical Oncology 29(1): 45-48, 1999

Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clinical Cancer Research 12(18): 5448-5453, 2006

DR2 blocker thioridazine: A promising drug for ovarian cancer therapy. Oncology Letters 14(6): 8171-8177, 2017

Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer. Neoplasma 58(3): 245-250, 2011

Survival in early-stage non-small cell lung cancer. Annals of Thoracic Surgery 60(2): 466-472, 1995

Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Science 100(10): 1917-1922, 2009

Vascular endothelial growth factor polymorphisms in early-stage non-small-cell lung cancer. Journal of Clinical Oncology 26(19): 3289-90; Author Reply 3290, 2008